FIZE Medical Secures $30M to Expand Kidney Health Technology Globally
20 January 2025•
%2Fuploads%2Fpr%2520articles%2F2025%2F01%2F20_3fizemedical.jpg&w=3840&q=75)
Dror Zerem, FIZE Medical CEO
Tel Aviv-based FIZE Medical, a leader in fluid management optimization, has raised $30 million in a Series A funding round. The $14 million Series A-4 round was led by Rapha Capital Management and its Rapha Capital PE Life Sciences Fund VI, with additional investments from Valitas Venture Capital and eHealth Ventures.
The funds will be used to expand FIZE Medical’s presence in the U.S., EU, and Asia and enhance its advanced technology. Led by CEO Dror Zerem, the company’s flagship product, FIZE-kUO®, detects early signs of kidney deterioration and supports real-time treatment adjustments using AI-enabled algorithms.
FIZE Medical is also preparing to launch AI-based predictive capabilities to serve as a Decision Support System (DSS), leveraging advanced data analysis to improve patient outcomes and prevent kidney damage.
Source: FinSMEs
%2Fuploads%2Fhealthtech%2Fcover18.jpg&w=3840&q=75)
